Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

<p>Supplemental Figure S5: Induction of apoptosis following 48 hr treatment of CLDN6 positive OVCA429 and CLDN6 negative M202 cells with a range of concentrations (50 μg/ml - 0.3658μg/ml) of CLDN6-23-ADC compared to control IgG ADC.</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Martina S.J. McDermott (15206951) (author)
Kolejni autorzy:	Neil A. O'Brien (15206954) (author), Benjamin Hoffstrom (15206957) (author), KeWei Gong (15206960) (author), Ming Lu (15206963) (author), Jun Zhang (15206966) (author), Tong Luo (15206969) (author), Min Liang (15206972) (author), Weiping Jia (15206975) (author), Jenny J. Hong (15206978) (author), Kevin Chau (15206981) (author), Simon Davenport (15206984) (author), Bin Xie (15206987) (author), Michael F. Press (15206990) (author), Richard Panayiotou (15206993) (author), Abram Handly-Santana (15206996) (author), Joan S. Brugge (9710515) (author), Leonard Presta (15206999) (author), John Glaspy (15207002) (author), Dennis J. Slamon (15047067) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Wydane: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Wydane: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Wydane: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Wydane: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Wydane: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Wydane: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Wydane: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Wydane: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
od: Santiago Duro-Sánchez (14959182)
Wydane: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
od: Yuncheng Bei (16546095)
Wydane: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
od: Yuncheng Bei (16546095)
Wydane: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
od: Yuncheng Bei (16546095)
Wydane: (2025)

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
od: Kristoffer Staal Rohrberg (15009138)
Wydane: (2025)

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
od: Kristoffer Staal Rohrberg (15009138)
Wydane: (2025)

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
od: Kristoffer Staal Rohrberg (15009138)
Wydane: (2025)

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
od: Kristoffer Staal Rohrberg (15009138)
Wydane: (2025)

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
od: Kristoffer Staal Rohrberg (15009138)
Wydane: (2025)

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
od: Kristoffer Staal Rohrberg (15009138)
Wydane: (2025)

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
od: Kristoffer Staal Rohrberg (15009138)
Wydane: (2025)

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
od: Kristoffer Staal Rohrberg (15009138)
Wydane: (2025)

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
od: Kristoffer Staal Rohrberg (15009138)
Wydane: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Wydane: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Wydane: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
od: Sheheryar Kabraji (15050565)
Wydane: (2025)

Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx
od: Yueren Fan (22687577)
Wydane: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Wydane: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Wydane: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Wydane: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Wydane: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Wydane: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Wydane: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Wydane: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Wydane: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Wydane: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Wydane: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
od: Niklas Klümper (15048887)
Wydane: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
od: Niklas Klümper (15048887)
Wydane: (2025)

Image 3_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.jpeg
od: Xi Chen (35903)
Wydane: (2025)

Table 2_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.docx
od: Xi Chen (35903)
Wydane: (2025)

Table 1_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.xlsx
od: Xi Chen (35903)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_74letsncsnlrf8olvlm1h6u3bg